MIRA Pharmaceuticals (NASDAQ:MIRA) Issues Quarterly Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) issued its earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03), FiscalAI reports.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA Pharmaceuticals stock traded down $0.00 during trading hours on Wednesday, hitting $0.64. The company’s stock had a trading volume of 30,911 shares, compared to its average volume of 266,712. MIRA Pharmaceuticals has a twelve month low of $0.51 and a twelve month high of $1.69. The firm has a fifty day moving average of $0.69 and a 200-day moving average of $0.92. The stock has a market cap of $26.77 million, a price-to-earnings ratio of -0.51 and a beta of 1.65.

Institutional Trading of MIRA Pharmaceuticals

A hedge fund recently bought a new position in MIRA Pharmaceuticals stock. BlackRock Inc. acquired a new position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 244,622 shares of the company’s stock, valued at approximately $232,000. BlackRock Inc. owned about 0.58% of MIRA Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 35.16% of the company’s stock.

Analyst Ratings Changes

MIRA has been the topic of several recent research reports. Weiss Ratings raised shares of MIRA Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Maxim Group began coverage on shares of MIRA Pharmaceuticals in a research report on Thursday, September 17th. They set a “buy” rating and a $3.50 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.50.

View Our Latest Research Report on MIRA Pharmaceuticals

About MIRA Pharmaceuticals

(Get Free Report)

MIRA Pharmaceuticals is a clinical-stage pharmaceutical company developing oral drug candidates for neurological and neuropsychiatric conditions. Its pipeline includes MIRA1a, an investigational synthetic cannabinoid analog being studied for potential use in conditions such as anxiety and chronic pain. The company has also added Ketamir-2, an investigational oral ketamine analog being developed for potential treatment of depression and neuropathic pain. These candidates remain in development and are not approved medicines.

Featured Articles

Earnings History for MIRA Pharmaceuticals (NASDAQ:MIRA)

Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.